| Literature DB >> 20470441 |
Joanne Baker1, Mei-Fong Ho, Anita Pelecanos, Michelle Gatton, Nanhua Chen, Salim Abdullah, Audrey Albertini, Frederic Ariey, John Barnwell, David Bell, Jane Cunningham, Djibrine Djalle, Diego F Echeverry, Dionicia Gamboa, Jeffery Hii, Myat Phone Kyaw, Jennifer Luchavez, Christopher Membi, Didier Menard, Claribel Murillo, Sina Nhem, Bernhards Ogutu, Pamela Onyor, Wellington Oyibo, Shan Qing Wang, James McCarthy, Qin Cheng.
Abstract
BACKGROUND: Accurate diagnosis is essential for prompt and appropriate treatment of malaria. While rapid diagnostic tests (RDTs) offer great potential to improve malaria diagnosis, the sensitivity of RDTs has been reported to be highly variable. One possible factor contributing to variable test performance is the diversity of parasite antigens. This is of particular concern for Plasmodium falciparum histidine-rich protein 2 (PfHRP2)-detecting RDTs since PfHRP2 has been reported to be highly variable in isolates of the Asia-Pacific region.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20470441 PMCID: PMC2893195 DOI: 10.1186/1475-2875-9-129
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Country Origins (ISO code) and number Plasmodium falciparum isolates sequenced for prfhp2 and pfhrp3 and the number of different pfhrp2 sequence types.
| Region/Country | Region/Country | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No. types | No. types | No. types | No. types | ||||||
| Benin (BJ) | 1 | 1 | Brazil (BR) | 9 | 6 | 2 | 1 | ||
| Burkina Faso (BF) | 1 | 1 | Colombia (CO) | 12 | 8 | 1 | 1 | ||
| Cameroon (CM) | 2 | 2 | Ecuador (EC) | 1 | 1 | ||||
| Central African Republic (CF) | 13 | 13 | 1 | 1 | Haiti (HT) | 10 | 6 | 4 | 4 |
| Gambia (GM) | 1 | 1 | 1 | 1 | Honduras (HN) | 3 | 2 | ||
| Ghana (GH) | 6 | 6 | Peru (PE) | 18 | 4 | 6 | 2 | ||
| Guinea (GN) | 1 | 1 | Santa Lucia (LC) | 1 | 1 | ||||
| Kenya (KE) | 30 | 30 | 6 | 6 | Suriname (SR) | 3 | 1 | 2 | 1 |
| Liberia (LR) | 3 | 3 | |||||||
| Madagascar (MG) | 17 | 17 | |||||||
| Malawi (MW) | 2 | 2 | Cambodia (KH) | 32 | 24 | 1 | 1 | ||
| Nigeria (NG) | 80 | 74 | 16 | 11 | China (CN) | 10 | 7 | 4 | 3 |
| Niger (NE) | 1 | 1 | Indonesia (ID) | 5 | 4 | ||||
| Sierra Leone (SL) | 2 | 2 | 1 | 1 | Malaysia (MY) | 2 | 2 | 1 | 1 |
| Sudan (SD) | 3 | 3 | Myanmar (MM) | 5 | 5 | ||||
| Tanzania (TZ) | 39 | 34 | 2 | 2 | Philippines (PH) | 45 | 27 | 7 | 4 |
| Uganda (UG) | 2 | 2 | Thailand (TH) | 7 | 6 | 4 | 4 | ||
| Zambia (ZM) | 2 | 2 | Vietnam (VN) | 5 | 4 | ||||
| Papua New Guinea (PG) | 17 | 12 | 7 | 6 | |||||
| Solomon Is. (SB) | 35 | 17 | 13 | 9 | |||||
| East Timor (TP) | 24 | 12 | |||||||
| Vanuatu (VU) | 8 | 4 | 1 | 0 | |||||
| 458 | 80 | ||||||||
The presence (+) and absence (-) of amino acid repeats in PfHRP2 and PfHRP3.
| Code | Repeat | PfHRP2 | PfHRP3 |
|---|---|---|---|
| 1 | AHHAHHVAD | + | + |
| 2 | AHHAHHAAD | + | + |
| 3 | AHHAHHAAY | + | - |
| 4 | AHH | + | + |
| 5 | AHHAHHASD | + | - |
| 6 | AHHATD | + | - |
| 7 | AHHAAD | + | + |
| 8 | AHHAAY | + | - |
| 9 | AAY | + | - |
| 10 | AHHAAAHHATD | + | - |
| 11 | AHN | + | - |
| 12 | AHHAAAHHEAATH | + | - |
| 13 | AHHASD | + | - |
| 14 | AHHAHHATD | + | - |
| 15 | AHHAHHAAN | - | + |
| 16 | AHHAAN | - | + |
| 17 | AHHDG | - | + |
| 18 | AHHDD | - | + |
| + | - | ||
| + | + | ||
| + | - | ||
| + | - | ||
| + | - | ||
| + | - |
Repeat types not previously reported are underlined.
The country (by ISO code) distribution of shared pfhrp2 and pfhrp3 sequences.
| a | SB, PH | u | KE, TP, TH | ao | NG |
| b | ID, NG | v | CN | ap | CO, HT |
| c | PG, VU | w | SB | aq | CO, PE |
| d | UG, KH, MY, PH | x | BR, PE, | ar | GH, NG |
| e | SB, PH | y | HN, LC | as | TH |
| f | SB, PH | z | NG | at | CO, KH |
| g | PH | aa | LR, PG | au | NG |
| h | SD, SB | ab | BR | av | NG, TZ, PE, KH |
| i | SB | ac | PH | aw | KH |
| j | PH | ad | HT | ax | KH |
| k | PH | ae | PH | ay | KH, ID, MM |
| l | PH | af | TP | az | KH |
| m | VN | ag | BR | ba | CO |
| n | VU | ah | CN | bb | NG |
| o | PH | ai | CN | bc | PH |
| p | TP | aj | BR, SR | bd | NG, TZ |
| q | SB | ak | NG | be | PG, ID |
| r | TP | al | NG | bf | NG, SB |
| s | SB | am | PG, SB | bg | SB |
| t | GH, PH, TH | an | PE | ||
| bh | PE | bn | CN, SR | bs | NG, SB |
| bi | KE, TH, CO, HT | bo | NG, CF, MY | bt | PG, SB, HT |
| bj | NG | bp | PG, SB | bu | PG, KH |
| bk | NG | bq | KE, PH | bv | NG, VU |
| bl | PH | br | PG, TH | bw | SB |
| bm | NG, CN, PE, BR | ||||
Figure 1Ratio of number of unique sequences to total sequences for . Numbers in brackets indicate the number of samples
Figure 2The length of PfHRP2 (number of aa) in countries with ≥5 samples. Numbers in brackets indicate the number of samples. The dotted line indicates the global mean. ^ The mean number is significantly higher than the global mean (p < 0.05); # the mean number is significantly lower than the global mean (p < 0.05)
Figure 3The number of type 2 repeat present in PfHRP2 in countries with ≥ 5 samples. Numbers in brackets indicate the number of samples. The dotted line indicates the global mean. ^ The mean number is significantly higher than the global mean (p < 0.05); # the mean number is significantly lower than the global mean (p < 0.05)
Figure 4The number of Type 7 repeat present in PfHRP2 in countries with ≥5 samples. Numbers in brackets indicate the number of samples. The dotted line indicates the global mean. ^ The mean number is significantly higher than the global mean (p < 0.05); # the mean number is significantly lower than the global mean (p < 0.05)